1. A method of treating or preventing a neurological disorder in a patient, comprising administering to a specified patient an anti-Nogo-A antibody or a functional fragment thereof in a dosage to achieve and maintain a colocalization level of said antibody with human Nogo-A on the cell membrane of said patient above 90% .2 . The method of claim 1, wherein the dosage of the anti-Nogo-A antibody is from 0.1 to 300 mg / kg. The method of claim 2, wherein the dosage of the anti-Nogo-A antibody is 15 mg / kg. The method of claim 3, wherein said colocalization level above 90% is maintained for 8 to 22 days. The method according to claim 4, wherein said colocalization level above 90% is maintained for 10 to 18 days. The method according to claim 5, wherein said colocalization level above 90% is maintained for 11 to 17 days. The method of claim 6, wherein said colocalization level above 90% is maintained for 12 to 16 days. The method of claim 6, wherein said colocalization level above 90% is maintained for 13 to 15 days. The method of claim 8, wherein said colocalization level above 90% is maintained for 14 days. A method for treating or preventing a neurological disorder in a patient, comprising administering to the indicated patient an anti-Nogo-A antibody or functional fragment thereof at a dosage of 15 mg / kg once every 14 days +/- 3 days. 11. The method according to any one of paragraphs. 1-10, where the anti-Nogo-A antibody is a monoclonal antibody. 12. The method according to any one of paragraphs. 1-10, where the anti-Nogo-A antibody is a humanized antibody. 13. The method according to any one of paragraphs. 1-10, where the anti-Nogo-A antibody contains H28L16.14. The method according to any one of paragraphs. 1-10, where the neurological disorder is selected from a stroke (ischemic or hemorrhagic), traumatic brain damage, spinal cord injury,1. Способ лечения или профилактики неврологического расстройства у пациента, включающий введение указанному пациенту антитела
